Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Fase II-onderzoek naar oncolytisch coxsackievirus A21 bij niet-resectabel melanoom
nov 2021 | Dermato-oncologie